Aller au contenu

Publications scientifiques

  • article Blanchette LJ, Bolduc M, Woldemariam T, Yousefi M, Rabezanahary H, Olivera-Ugarte SM, Garneau C, Angers M, Shi R, Flamand L, Baz M, Vidal S, Falzarano D, Lemay JF, Leclerc D

    Engineering a Modular PapMV Nanoparticle Vaccine: Comparative Efficacy of a Covalent and a Non-Covalent N-Antigen Vaccine Against Emerging SARS-CoV-2 Variants

    Vaccines (Basel) 14 (4), 2026.

    DOI PUBMED
  • article Bolduc M, Saint-Louis P, Carignan D, Garneau C, Breton Y, Pelletier M, Rancourt A, Satoh MS, Sato S, Gilbert M, Rabezanahary H, Baz M, Dubuc I, Flamand L, Leclerc D

    PapMV nanoparticles: A novel pathway to SARS-CoV-2 protection, distinct from Imidazoquinolines

    Nanomedicine 71 2026.

    DOI PUBMED
  • article Bourguignon L, Hétu-Arbour R, Charpentier T, Bolduc M, Leclerc D, Heinonen KM, Lamarre A

    Systemic administration of a viral nanoparticle neoadjuvant prevents lung metastasis development through emergency myelopoiesis

    Oncoimmunology 13 (1), 2024.

    DOI PUBMED
  • article Dash S, Farnós O, Yang Z, Sudalaiyadum Perumal A, Chaves Fulber JP, Venereo-Sánchez A, Leclerc D, Kamen AA

    A rapid procedure to generate stably transfected HEK293 suspension cells for recombinant protein manufacturing: Yield improvements, bioreactor production and downstream processing

    Protein Expr Purif 210 2023.

    DOI PUBMED
  • article Olivera-Ugarte SM, Bolduc M, Laliberté-Gagné MÈ and Blanchette LJ, Garneau C, Fillion M, Savard P, Dubuc I, Flamand L, Farnòs O, Xu X, Kamen A, Gilbert M, Rabezanahary H, Scarrone M, Couture C, Baz M, Leclerc D

    A nanoparticle-based COVID-19 vaccine candidate elicits broad neutralizing antibodies and protects against SARS-CoV-2 infection

    Nanomedicine 44 2022.

    DOI PUBMED
  • article Possamaï D, Hanafi LA, Bellemare-Pelletier A, Hamelin K, Thébault P, Hébert MJ, Gagnon É and Leclerc D, Lapointe R

    MHC class I antigen cross-presentation mediated by PapMV nanoparticles in human antigen-presenting cells is dependent on autophagy

    PLoS One 16 (12), 2021.

    DOI PUBMED
  • article Laliberte-Gagne ME, Bolduc M, Garneau C, Olivera-Ugarte SM, Savard P, Leclerc D

    Modulation of Antigen Display on PapMV Nanoparticles Influences Its Immunogenicity

    Vaccines (Basel) 9 (1), 2021.

    DOI PUBMED
  • article Langley J, Pastural E, Halperin S, McNeil S, ElSherif M, MacKinnon-Cameron D, Ye L, Grange C, Thibodeau V, Cailhier JF, Lapointe R, McElhaney J, Martin L, Bolduc M, Laliberté-Gagné ME, Leclerc D, Savard P

    A Randomized Controlled Study to Evaluate the Safety and Reactogenicity of a Novel rVLP-Based Plant Virus Nanoparticle Adjuvant Combined with Seasonal Trivalent Influenza Vaccin…

    Vaccines (Basel) 8 (3), 2020.

    DOI PUBMED
  • article Farnos O, Venereo-Sanchez A, Xu X, Chan C, Dash S, Chaabane H, Sauvageau J, Brahimi F, Saragovi U, Leclerc D, Kamen AA

    Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation

    Vaccines (Basel) 8 (4), 2020.

    DOI PUBMED
  • article Laliberte-Gagne ME, Bolduc M, Therien A, Garneau C, Casault P, Savard P, Estaquier J, Leclerc D

    Increased Immunogenicity of Full-Length Protein Antigens through Sortase-Mediated Coupling on the PapMV Vaccine Platform

    Vaccines (Basel) 7 (2), 2019.

    DOI PUBMED
  • article Carignan D, Herblot S, Laliberte-Gagne ME, Bolduc M, Duval M, Savard P, Leclerc D

    Activation of innate immunity in primary human cells using a plant virus derived nanoparticle TLR7/8 agonist

    Nanomedicine 14 (7), 2018.

    DOI PUBMED
  • article Bolduc M, Baz M, Laliberté-Gagné MÈ and Carignan D, Garneau C, Russel A, Boivin G, Savard P, Leclerc D

    The quest for a nanoparticle-based vaccine inducing broad protection to influenza viruses

    Nanomedicine 14 (8), 2018.

    DOI PUBMED